The basics:
- Quest Diagnostics launches consumer blood test for PFAS
- Secaucus-based testing provider also expands heavy metal blood and urine panels
- Ashwini Dumaswala leads environmental toxicology team, discusses new offerings
- Survey finds over 70% of Americans concerned about chemical exposure
Amid growing public health concerns about environmental contaminants, Quest Diagnostics is expanding its focus on testing that can help consumers better understand their exposure to potentially harmful chemicals.
Over the past two-and-a-half years, the Secaucus-based testing provider has unveiled one of the industry’s first consumer-accessible blood tests that can detect and measure per- and polyfluorinated alkyl substances (PFAS), as well as an expanded heavy metal blood and urine panels for determining levels of toxic elements like arsenic, cadmium, lead, mercury, cobalt and thallium.
One of the nation’s largest medical laboratory operators, Quest provides testing and related services to physicians, hospitals, health plans and patients. Its test offerings – which span routine bloodwork, cancer screening, genetic testing and specialized diagnostics – are available to more than 90% of U.S. insured lives, according to the company.
Quest serves approximately one-third of American adults annually through its 7,770-plus patient access points across North America. It also handles testing for half of the physicians and hospitals in the U.S. each year.
Growing area of interest
As part of an effort to accelerate development of tests addressing public health concerns about environmental exposures, Quest formalized its broader environmental toxicology work into a dedicated franchise last year.
Ashwini Dumaswala, vice president and general manager for Quest’s drug monitoring and environmental toxicology team, said, “We try to identify emerging needs and develop innovative solutions that illuminate insights into an individual’s health while making testing simpler and more accessible for communities and organizations who are trying to manage their environmental risks.
“Environmental toxicology is really an area of interest that’s been growing over the last few years, especially as awareness around the potential health impacts of toxins like PFAS, also known as forever chemicals, and microplastics has been increasing,” said Dumaswala, a 20-plus year veteran of the healthcare and consumer health space.
“And research into these impacts is emerging. I mean, we see an article in the news almost daily about an environmental toxin,” she said. “The science around testing is also evolving, because I would say maybe five or 10 years ago, we didn’t have good ways to measure the body burden for some of these toxins or chemicals. So today, what was once invisible can now actually be measured.”
‘Path for better health’
A February 2026 survey by The Pew Charitable Trusts found that more than 70% of Americans were concerned about their own or their families’ exposure to harmful chemicals in food and drinking water. About 5 in 6 said government and businesses should do more to ensure chemical safety, according to the results.
Additionally, a national voter poll conducted in October 2024 by advocacy group Water Hub revealed 88% of respondents were worried about PFAS and lead pipes as threats to drinking water safety.
Dumaswala said, “As more people become aware of the implications and the health impacts of these environmental toxins, we’re seeing an increased interest around these tests, and it really reinforces the need for clinically validated testing so that we can really understand the impacts on health.”
“The one thing to remember as we think about these environmental toxin tests, the presence of an environmental toxin in someone’s blood really doesn’t mean that someone is definitively going to develop a health condition, but it does mean that that individual may be at higher risk for certain health conditions,” she explained. “So, having these insights really illuminates the path for better health.”

According to the U.S. Centers for Disease Control and Prevention, exposure to PFAS has been associated with health risks such as increased cholesterol levels, liver enzyme changes, reduced immune response to some vaccines, pregnancy-related high blood pressure and lower birth weights. It’s also been linked to certain cancers, including kidney and testicular.
Depending on the substance, exposure to heavy metals and metalloids can damage the brain and nervous system, kidneys and other organs, the CDC says. Lead can cause anemia, kidney damage and neurological problems, while mercury can affect memory, coordination and learning. Arsenic has been shown to increase the risk of skin, lung and bladder cancers, according to the CDC.
“We’re continuing to monitor the science across multiple environmental toxins, and the science is emerging. And so, as we monitor what’s emerging from a scientific perspective and what’s emerging in the literature, that will define our roadmap of moving forward,” Dumaswala said.
Where PFAS are found
Quest began working on a PFAS panel after a 2022 report from the National Academies of Science, Engineering and Medicine (NASEM) urged the CDC to start encouraging blood testing for people with likely histories of elevated PFAS exposure. It also recommended the guidance include ongoing health monitoring of individuals with elevated levels.
PFAS can be found in non-stick cookware, fast-food packaging and water-resistant household products. They are potentially harmful because they can accumulate and linger in the body.
Populations who have likely had elevated exposure include firefighters or those who used a water supply near a commercial or industrial location, along with anyone who lives near a facility that manufactures fluorochemicals or areas of documented PFAS environmental contamination, according to Quest.
A U.S. Geological Survey study from 2023 estimated that at least 45% of the nation’s tap water contains one or more types of PFAS. Given the prevalence, the CDC’s Agency for Toxic Substances and Disease Registry says nearly everyone in the country has measurable PFAS in their blood.
While there are no approved medical treatments to remove PFAS from the body, researchers are exploring whether dietary interventions, including increased fiber and folate intake, could help reduce the chemicals’ accumulation. Early findings have been promising, but more research is needed to determine whether these approaches can lower PFAS levels in humans.
“When this [NASEM] report was published, we realized that there was an opportunity for us to continue to bring innovative testing that could help illuminate the impacts of environmental toxins on a patient’s health,” Dumaswala said.
How does the test work?
After buying the test online at questhealth.com, individuals are prompted to schedule an appointment at one of Quest’s 2,000 patient service centers for a blood draw. The results will later be made available on a secure patient portal and delivered in a clear, easy-to-read report that includes information on ways to reduce exposure risk.
According to Dumaswala, Quest’s PFAS panel includes measurement of the nine chemicals identified in the NACEM report that have been associated with certain health risks. “What we provide is an overall summation … and the amount that’s in an individual’s body, as well as the individual levels,” she explained.

Dumaswala noted the test cannot determine where exposure occurred, predict future health problems or tell someone what treatment they need. “It really empowers the individual to take control of their health and have conversations with their clinician around, what do those levels mean and what is an action plan that they can pursue,” she explained. “And that action plan may include things like trying to identify the source of the PFAS exposure. It could entail staying on top of health screenings or in some cases maybe being screened more frequently for certain health conditions or maybe even trying an emerging treatment like a probiotic, a folate or fiber supplementation.”
[The test] empowers the individual to take control of their health and have conversations with their clinician around, what do those levels mean and what is an action plan that they can pursue.
– Ashwini Dumaswala, VP and GM, Quest Diagnostics drug monitoring and environmental toxicology team
The PFAS test includes the option of a phone consultation to discuss results with a licensed physician through the independent physician network that orders the test. In addition, they can share details with other doctors, such as their regular primary care physician.
For consumers, tests purchased directly through Quest Health are paid out of pocket and are not eligible for insurance reimbursement. However, physician-ordered tests through Quest Diagnostics may be billed to insurance, depending on the patient’s health plan and medical necessity.
According to its website, the PFAS panel costs $350, plus a $7 physician service fee, while the expanded heavy metals panel costs $185, plus a $6 service fee. The basic heavy metals panel sells for $120 plus a $6 physician service fee.
Getting testy
One of the biggest challenges is educating consumers about the potential health effects of environmental exposures and the role testing can play, according to Dumaswala. A 2026 study published in Ecological Economics found that public concern around PFAS contamination does not necessarily translate into demand for testing. In an experiment involving 1,005 adults in the Mid-Atlantic region, researchers learned that while people may be worried, they were less willing to pay to find out if they had been exposed.
According to the report, participants were willing to pay an average of just 11.2% of a PFAS test’s retail price, compared with 16.4% for a water filter designed to remove the chemicals. Consumer education remains an issue, but the study found that providing information about PFAS health risks alongside media coverage may be one of the most effective ways to reach the public. Because the field is still developing, Dumaswala said another hurdle has been “creating awareness around what an individual does with their results.”
Dumaswala declined to share revenue figures or the number of PFAS tests performed. But, she added, Quest has “seen consistent demand” since the spring 2024 launch. “And until we made this test available, there were really limited options that were available for individuals to understand their PFAS levels,” Dumaswala said. “We’ve made it accessible across the country at a national level to consumers as well as individuals. And really what we’re trying to do is make testing smarter, simpler, and more accessible.”
“Contamination has affected so many communities in New Jersey, so it does make it more meaningful to us locally,” Dumaswala said. “I do have family members, for example, that are firefighters and they are at higher risk for exposure, and it does make it that much more meaningful and personal.”
In legal terms
New Jersey has been at the center of several major legal battles over PFAS contamination. Some of the biggest cases include:
- August 2025: DuPont, Chemours and Corteva reached a settlement valued at more than $2 billion to address contamination at four industrial sites: Chambers Works in Salem County, Parlin in Middlesex County, Repauno in Gloucester County and Pompton Lakes Works in Passaic County. The agreement authorized by a federal judge in August 2026 includes up to $1.2 billion for site remediation, $365 million for natural resource damages and up to $795 million for statewide PFAS abatement. The companies must fully remediate the four industrial sites, regardless of the ultimate cost.
- May 2025: 3M agreed to pay New Jersey up to $450 million to resolve PFAS contamination claims involving its Chambers Works facility in Pennsville and Carneys Point and its Parlin site in Sayreville (Middlesex County), as well as statewide claims involving PFAS-containing firefighting foam. The settlement approved this past summer by a federal judge includes funding for environmental cleanup, drinking water treatment and restoration of natural resources. Payments will be made over 25 years.
- May 2024: Arkema said it would pay $33.95 million to address contamination associated with its former ownership of the West Deptford manufacturing site. The settlement approved last year by the court includes $12.7 million for natural resource damages and $21.25 million for cleanup projects, including drinking water treatment. The company also agreed to maintain a $75 million financial reserve to help ensure remediation is completed.
- June 2023: Solvay Specialty Polymers agreed to a $393.8 million settlement to address PFAS and other contamination around its manufacturing facility in West Deptford. The agreement requires the company to fund environmental investigations and cleanup, support upgrades to public water systems, investigate contamination in nearby private wells and compensate the state for damage to natural resources. A court approved the settlement in March 2024.
Since 2019, the state has recovered more than $3 billion to help fund environmental cleanup, drinking water improvements and natural resource restoration.
“But from speaking with advocates and researchers across the county, I know we’re not the only state that’s concerned. You have states like New Hampshire, Maine and Michigan that have an extremely high amount of PFAS exposure in their soil and in their agricultural products. And there’s a concern by those states about … the individuals who live in their communities. And we have the same concern in New Jersey, and that’s why it was so important for us to make this testing simpler, make it smarter and make it more accessible,” Dumaswala said.
Getting the word out
Quest makes the PFAS test available via B2B channels for organizations seeking workforce community or research-based testing for at-risk populations due to concerns about elevated PFAS exposure.
The company has also partnered with states and public health organizations to connect with communities that have known environmental contamination concerns.
Quest’s collaborations include teaming up with Maine officials to develop a more comprehensive PFAS panel for residents concerned about contamination associated with the use of wastewater sludge as fertilizer. The company also serves as the laboratory partner for a National Minority Quality Forum initiative examining cancer rats and potential links to PFAS in Houston’s Fifth Ward, a designated cancer cluster. And Quest provides lead testing to communities affected by the 2025 Palisades wildfires and partnered with Function Health to offer free PFAS testing to first responders.
Dumaswala said, “This is an area that’s very near and dear to my heart. I read the news every day as most people do, and I see the headlines, and there’s a new article every day about an environmental toxin. Scientists are really learning more about the potential impact of a range of these environmental toxins on human health.”
“And I think it’s a really interesting time where you have growing concern, you have increased involvement from government agencies who are also concerned and increased concern from different organizations and research organizations to really try and understand what the health impacts of these toxins are,” she said. “And it’s a time to be at Quest where we’re growing our portfolio and making these tests accessible to aid in a detection of a wider range of health impacts. Many of these tests can support preventative care and help to eliminate that path to better health for our patients.”
The post Quest Diagnostics expands PFAS, heavy metals testing appeared first on NJBIZ.

